2. Others
  3. Isotope-Labeled Compounds
  4. 2012598-41-1

2012598-41-1

Acipimox-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N<sub>2</sub> Chemical Structure

2012598-41-1

Chemical Structure

  • Acipimox-13C2,15N2
  • Synonym(s): K-9321-13C2,15N2
  • CAS No: 2012598-41-1
    Formula: C413C2H615N2O3
    Molecular Weight: 158.10
  • InChIKey: DJQOOSBJCLSSEY-WKHKRNGSSA-N
  • SMILES: O=[13C]([13C]1=C[15N+]([O-])=C(C)C=[15N]1)O

Biological Activity: Acipimox-13C2,15N2 (K-9321-13C2,15N2) is 13C- and 15N-labeled Acipimox (HY-B0283)[1].

Cat. No. Product Name Purity Description
HY-B0283S1 Acipimox-13C2,15N2 Acipimox-13C2,15N2 (K-9321-13C2,15N2) is 13C- and 15N-labeled Acipimox (HY-B0283).
HY-B0283S Acipimox-d4 Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
HY-B0283 Acipimox 99.58% Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
HY-B0283R Acipimox (Standard) ≥98% Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

Keywords:

Acipimox-13C2,15N2Acipimox-d4AcipimoxAcipimox (Standard)